Clinical trials: Neoplasia GI
Gastric Adenocarcinoma
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT02494583
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Volunteers
- 763 people
- Sponsor
- Merck Sharp & Dohme LLC
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Colonic Neoplasms
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III colon cancer. Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS), safety (including long term…
- Trial name
- NCT00275210
- Testing
- Oxaliplatin (SR96669)
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,246 people
- Sponsor
- Sanofi
Advanced Cancer, Squamous Cell Carcinoma
A Phase 1 Study in Participants With Advanced Cancer
The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or metastatic cancer (Part A), or squamous cell…
- Conditions
- Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV
- Trial name
- NCT01115790
- Testing
- Prexasertib
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not…
- Trial name
- NCT00555620
- Testing
- capecitabine, oxaliplatin, sunitinib malate
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
- Trial name
- NCT04616196
- Testing
- NKTR-255, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Solid Tumors, Colorectal Cancer
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT06806046
- Testing
- M9140
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Adenomatous Polyposis Coli
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
- Trial name
- NCT00140894
- Testing
- MK0966; rofecoxib / Duration of Treatment: 24 weeks
- Volunteers
- 62 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Cancer, Rectal Cancer
Clinical Trial in Patients With Metastatic Colorectal Cancer
The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and…
- Trial name
- NCT00081627
- Testing
- CoFactor and 5FU
- Where
- 9 sites in United States, Serbia and Montenegro
- Volunteers
- 48 people
- Sponsor
- Mast Therapeutics, Inc.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Colorectal Cancer
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic…
- Trial name
- NCT03799731
- Testing
- GM102, Trifluridine/Tipiracil, GM102 expansion
- Where
- 5 sites in Belgium, Czechia
- Volunteers
- 65 people
- Sponsor
- GamaMabs Pharma
Cancer, Carcinoma
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
- Conditions
- Cancer, Carcinoma, Colon Cancer, Colorectal Cancer
- Trial name
- NCT00752570
- Testing
- AMG 386, FOLFIRI
- Volunteers
- 144 people
- Sponsor
- Amgen
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Carcinoma
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
This study is designed to evaluate the efficacy and safety of icotinib in treating advanced carcinoma of the gastroesophageal junction and esophagus with EGFR overexpression (IHC 3+) or positive FISH, the primary endpoint is…
- Trial name
- NCT01855854
- Testing
- Icotinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
CRC, Colorectal Cancer
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants…
- Trial name
- NCT07805551
- Testing
- HDM2017, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.